Cargando…

Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?

BACKGROUND: The identification of biomarkers of transition from the at-risk mental state (ARMS) to psychotic disorder is important because early treatment of psychosis is associated with improved outcome. Increasing evidence points to an inflammatory contribution to psychosis. We questioned whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Föcking, Melanie, Dicker, Patrick, Lopez, Lorna M., Cannon, Mary, Schäfer, Miriam R., McGorry, Patrick D., Smesny, Stefan, Cotter, David R., Amminger, G. Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029014/ https://www.ncbi.nlm.nih.gov/pubmed/27650124 http://dx.doi.org/10.1186/s12888-016-1039-7

Ejemplares similares

Erythrocyte glutathione levels as long-term predictor of transition to psychosis
por: Lavoie, S, et al.
Publicado: (2017)

Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study
por: Amminger, G. Paul, et al.
Publicado: (2015)

Recent Meta-Analyses in the Clinical High Risk for Psychosis Population: Clinical Interpretation of Findings and Suggestions for Future Research
por: Nelson, Barnaby, et al.
Publicado: (2018)

Prediction of transition from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers
por: Clark, S R, et al.
Publicado: (2016)

Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis
por: Berger, Gregor E., et al.
Publicado: (2016)

Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
por: Nelson, Barnaby, et al.
Publicado: (2020)

Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence
por: Mongan, David, et al.
Publicado: (2021)

T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL
por: Schlögelhofer, Monika, et al.
Publicado: (2020)

Early Intervention in Psychosis: Obvious, Effective, Overdue
por: McGorry, Patrick D.
Publicado: (2015)

Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
por: Amminger, G P, et al.
Publicado: (2015)

White matter integrity in individuals at ultra-high risk for psychosis: a systematic review and discussion of the role of polyunsaturated fatty acids
por: Vijayakumar, Nandita, et al.
Publicado: (2016)

Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study
por: Kim, Sung-Wan, et al.
Publicado: (2016)

Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
por: Susai, Subash Raj, et al.
Publicado: (2022)

S8. RELATIONSHIP BETWEEN ALLOSTATIC LOAD AND POOR FUNCTIONAL CAPACITY IN YOUTH AT ULTRA-HIGH RISK FOR PSYCHOSIS
por: Berger, Maximus, et al.
Publicado: (2018)

Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case–Control Study of the ALSPAC Longitudinal Birth Cohort
por: English, Jane A, et al.
Publicado: (2018)

S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING
por: Yuen, Hok Pan, et al.
Publicado: (2018)

T30. TIPPING POINTS – PREDICTING TRANSITIONS TO PSYCHOSIS IN AT-RISK YOUNG PEOPLE
por: Hartmann, Jessica A, et al.
Publicado: (2018)

“Attenuated psychotic symptoms syndrome” as a risk syndrome of psychosis, diagnosis in DSM-V: The debate
por: Shrivastava, Amresh, et al.
Publicado: (2011)

Discharge destinations for young people with a first episode of psychosis after attending an early intervention for psychosis service
por: O’Donoghue, Brian, et al.
Publicado: (2023)

O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL
por: Allott, Kelly, et al.
Publicado: (2018)

Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis
por: Heurich, Meike, et al.
Publicado: (2021)

Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress
por: Föcking, Melanie, et al.
Publicado: (2019)

Using clinical information to make individualized prognostic predictions in people at ultra high risk for psychosis
por: Mechelli, Andrea, et al.
Publicado: (2017)

Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis
por: Bousman, C A, et al.
Publicado: (2013)

Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study
por: Berger, M E, et al.
Publicado: (2017)

M22. IGG ANTIBODIES TO TOXOPLASMA GONDII ARE ASSOCIATED WITH INCREASED LONG-TERM RISK FOR PSYCHOSIS IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS
por: Berger, Maximus, et al.
Publicado: (2020)

PM485. Association between erythrocyte membrane fatty acids and psychopathology in individuals at ultra-high risk for psychosis
por: Jhon, Min, et al.
Publicado: (2016)

Gender differences in first episode psychotic mania
por: Cotton, Sue M, et al.
Publicado: (2013)

Persistent negative symptoms in individuals at Ultra High Risk for psychosis
por: Yung, Alison R., et al.
Publicado: (2019)

T44. A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE EFFECTS OF VITAMIN B12, B6 AND FOLIC ACID ON COGNITION AND SYMPTOMS IN FIRST-EPISODE PSYCHOSIS: THE VITAMINS IN PSYCHOSIS STUDY
por: Allott, Kelly, et al.
Publicado: (2018)

The Positive and Negative Experiences of Caregiving for Siblings of Young People with First Episode Psychosis
por: Bowman, Siann, et al.
Publicado: (2017)

T21. DEVELOPMENT OF PROTEOMIC PREDICTION MODELS FOR OUTCOMES IN THE CLINICAL HIGH RISK STATE AND PSYCHOTIC EXPERIENCES IN ADOLESCENCE: MACHINE LEARNING ANALYSES IN TWO NESTED CASE-CONTROL STUDIES
por: Mongan, David, et al.
Publicado: (2020)

T121. RATES AND PREDICTORS OF RELAPSE FOLLOWING DISCONTINUATION OF ANTIPSYCHOTIC MEDICATION AFTER A FIRST EPISODE OF PSYCHOSIS
por: Bowtell, Meghan, et al.
Publicado: (2018)

F130. INCREASED RISK OF PSYCHOTIC DISORDERS IN AFRICAN MIGRANTS TO AUSTRALIA
por: Downey, Linglee, et al.
Publicado: (2018)

O1.7. PROTEOMIC ANALYSIS OF BLOOD BASED SAMPLES FROM THE OPTiMiSE (OPTIMIZATION OF TREATMENT AND MANAGEMENT OF SCHIZOPHRENIA IN EUROPE) STUDY POINT TOWARDS COMPLEMENT PATHWAY PROTEIN CHANGES
por: Föcking, Melanie, et al.
Publicado: (2018)

NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course
por: Nelson, B., et al.
Publicado: (2018)

M21. THE STEP TRIAL: A SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMISED TRIAL (SMART) OF INTERVENTIONS FOR PATIENTS AT ULTRA-HIGH RISK OF PSYCHOSIS - STUDY RATIONALE, DESIGN AND BASELINE DATA
por: Nelson, Barnaby, et al.
Publicado: (2020)

Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment
por: McGorry, Patrick D., et al.
Publicado: (2011)

Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial
por: Cheng, Nicholas, et al.
Publicado: (2022)

A single-blind, randomised controlled trial of a physical health nurse intervention to prevent weight gain and metabolic complications in first-episode psychosis: the Physical Health Assistance in Early Psychosis (PHAstER) study
por: O'Donoghue, Brian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jl445ach1s62883qsjbvu33dis